Literature DB >> 23519896

Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation.

Timo Gaber1, Cam Loan Tran, Saskia Schellmann, Martin Hahne, Cindy Strehl, Paula Hoff, Andreas Radbruch, Gerd-Rüdiger Burmester, Frank Buttgereit.   

Abstract

Inflamed areas are characterized by infiltration of immune cells, local hypoxia and alterations of cellular redox states. We investigated the impact of hypoxia on survival, proliferation, cytokine secretion, intracellular energy and redox state of human CD4(+) T cells. We found that pathophysiological hypoxia (<2% O2 ) significantly decreased CD4(+) T-cell survival after mitogenic stimulation. This effect was not due to an increased caspase-3/7-mediated apoptosis or adenosine-5'-triphosphate (ATP) consumption/depletion. However, the ability of stimulated T cells to proliferate was reduced under hypoxic conditions, despite increased expression of CD25. Pathophysiological hypoxia was also found to modify intracellular ROS (iROS) levels in stimulated T cells over time as compared with levels found in normoxia. Physiological hypoxia (5% O2 ) did not decrease CD4(+) T-cell survival and proliferation or modify iROS levels as compared with normoxia. We conclude that pathophysiological hypoxia affects T-cell proliferation and viability via disturbed IL-2R signalling downstream of STAT5a phosphorylation, but not as a result of impaired cellular energy homeostasis. We suggest iROS links early events in T-cell stimulation to the inhibition of the lymphoproliferative response under pathophysiological hypoxic conditions. The level of iROS may therefore act as a mediator of immune functions leading to down-regulation of long-term T-cell activity in inflamed tissues.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519896     DOI: 10.1002/eji.201242754

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  In the eye of the storm: T cell behavior in the inflammatory microenvironment.

Authors:  Robert Haas; Federica Marelli-Berg; Claudio Mauro
Journal:  Am J Clin Exp Immunol       Date:  2013-06-15

Review 2.  T-cell metabolism in autoimmune disease.

Authors:  Zhen Yang; Eric L Matteson; Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2015-02-11       Impact factor: 5.156

Review 3.  Hypoxia and antitumor CD8+ T cells: An incompatible alliance?

Authors:  Romain Vuillefroy de Silly; Pierre-Yves Dietrich; Paul R Walker
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

Review 4.  Metabolic Adaptations of CD4+ T Cells in Inflammatory Disease.

Authors:  Cristina Dumitru; Agnieszka M Kabat; Kevin J Maloy
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

5.  Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells.

Authors:  Romain Vuillefroy de Silly; Laura Ducimetière; Céline Yacoub Maroun; Pierre-Yves Dietrich; Madiha Derouazi; Paul R Walker
Journal:  Eur J Immunol       Date:  2015-05-26       Impact factor: 5.532

Review 6.  Metabolic Checkpoints in Differentiation of Helper T Cells in Tissue Inflammation.

Authors:  Suyasha Roy; Zaigham Abbas Rizvi; Amit Awasthi
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

7.  Age-related increase of mitochondrial content in human memory CD4+ T cells contributes to ROS-mediated increased expression of proinflammatory cytokines.

Authors:  Yuling Chen; Yuanchun Ye; Pierre-Louis Krauß; Pelle Löwe; Moritz Pfeiffenberger; Alexandra Damerau; Lisa Ehlers; Thomas Buttgereit; Paula Hoff; Frank Buttgereit; Timo Gaber
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

8.  Hypoxia Selectively Impairs CAR-T Cells In Vitro.

Authors:  Robert Berahovich; Xianghong Liu; Hua Zhou; Elias Tsadik; Shirley Xu; Vita Golubovskaya; Lijun Wu
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.